Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark

被引:53
作者
Hjorthoj, Carsten [1 ,2 ,3 ,4 ]
Posselt, Christine Merrild [1 ]
Nordentoft, Merete [1 ,3 ,4 ]
机构
[1] Copenhagen Univ Hosp, Copenhagen Res Ctr Mental Hlth CORE, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Publ Hlth, Sect Epidemiol, Copenhagen, Denmark
[3] iPsych, Lundbeck Fdn Initiat Integrat Psychiat Res, Copenhagen, Denmark
[4] iPsych, Lundbeck Fdn Initiat Integrat Psychiat Res, Aarhus, Denmark
关键词
SPECTRUM DISORDERS; METAANALYSIS; ASSOCIATION;
D O I
10.1001/jamapsychiatry.2021.1471
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
IMPORTANCE Cannabis use and potency of cannabis have increased during the past 2 decades. If the association between cannabis use and schizophrenia is causal, this should be reflected in an increase in the proportion of cases of schizophrenia being attributable to cannabis, the population-attributable risk fraction (PARE). OBJECTIVE To determine whether the PARE for cannabis use disorder in schizophrenia has increased over time. DESIGN, SETTING, AND PARTICIPANTS This nationwide, register-based historical prospective cohort study included all people in Denmark born before December 31, 2000, who were alive and 16 years or older at some point from January 1,1972, to December 31, 2016. Data analysis was performed from August 2020 to April 2021. EXPOSURE Diagnosis of cannabis use disorder. MAIN OUTCOMES AND MEASURES Diagnosis of schizophrenia, with estimated PARE of cannabis use disorder in schizophrenia from 1972 to 2016. RESULTS A total of 7186 834 individuals were included in the analysis, including 3 595 910 women (50.0%) and 3 590 924 men (50.0%). The adjusted hazard ratio for schizophrenia fluctuated at approximately 4 (with 95% Cls ranging from approximately 3 to 6) throughout most of the study period when people diagnosed with cannabis use disorder were compared with those without cannabis use disorder. The PARF of cannabis use disorder in schizophrenia also fluctuated, but with clear evidence of an increase from 1995 (when the PARE was relatively stable around 2.0%, with a 95% CI of approximately 0.3% to either side) until reaching some stability around 6.0% to 8.0% (with a 95% CI of approximately 0.5% to either side) since 2010. CONCLUSIONS AND RELEVANCE The results from these longitudinal analyses show the proportion of cases of schizophrenia associated with cannabis use disorder has increased 3- to 4-fold during the past 2 decades, which is expected given previously described increases in the use and potency of cannabis. This finding has important ramifications regarding legalization and control of use of cannabis.
引用
收藏
页码:1013 / 1019
页数:7
相关论文
共 36 条
[1]   Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses [J].
Belbasis, L. ;
Kohler, C. A. ;
Stefanis, N. ;
Stubbs, B. ;
van Os, J. ;
Vieta, E. ;
Seeman, M. V. ;
Arango, C. ;
Carvalho, A. F. ;
Evangelou, E. .
ACTA PSYCHIATRICA SCANDINAVICA, 2018, 137 (02) :88-97
[2]   A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia [J].
Davies, G ;
Welham, J ;
Chant, D ;
Torrey, EF ;
McGrath, J .
SCHIZOPHRENIA BULLETIN, 2003, 29 (03) :587-593
[3]   The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study [J].
Di Forti, Marta ;
Quattrone, Diego ;
Freeman, Tom P. ;
Tripoli, Giada ;
Gayer-Anderson, Charlotte ;
Quigley, Harriet ;
Rodriguez, Victoria ;
Jongsma, Hannah E. ;
Ferraro, Laura ;
La Cascia, Caterina ;
La Barbera, Daniele ;
Tarricone, Ilaria ;
Berardi, Domenico ;
Szoke, Andrei ;
Arango, Celso ;
Tortelli, Andrea ;
Velthorst, Eva ;
Bernardo, Miguel ;
Del-Ben, Cristina Marta ;
Menezes, Paulo Rossi ;
Selten, Jean-Paul ;
Jones, Peter B. ;
Kirkbride, James B. ;
Rutten, Bart P. F. ;
de Haan, Lieuwe ;
Sham, Pak C. ;
van Os, Jim ;
Lewis, Cathryn M. ;
Lynskey, Michael ;
Morgan, Craig ;
Murray, Robin M. .
LANCET PSYCHIATRY, 2019, 6 (05) :427-436
[4]   Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study [J].
Di Forti, Marta ;
Marconi, Arianna ;
Carra, Elena ;
Fraietta, Sara ;
Trotta, Antonella ;
Bonomo, Matteo ;
Bianconi, Francesca ;
Gardner-Sood, Poonam ;
O'Connor, Jennifer ;
Russo, Manuela ;
Stilo, Simona A. ;
Marques, Tiago Reis ;
Mondelli, Valeria ;
Dazzan, Paola ;
Pariante, Carmine ;
David, Anthony S. ;
Gaughran, Fiona ;
Atakan, Zerrin ;
Iyegbe, Conrad ;
Powell, John ;
Morgan, Craig ;
Lynskey, Michael ;
Murray, Robin M. .
LANCET PSYCHIATRY, 2015, 2 (03) :233-238
[5]   Increasing potency and price of cannabis in Europe, 2006-16 [J].
Freeman, Tom P. ;
Groshkova, Teodora ;
Cunningham, Andrew ;
Sedefov, Roumen ;
Griffiths, Paul ;
Lynskey, Michael T. .
ADDICTION, 2019, 114 (06) :1015-1023
[6]   Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia [J].
Gillespie, Nathan A. ;
Kendler, Kenneth S. .
JAMA PSYCHIATRY, 2021, 78 (05) :467-468
[7]  
Greenland S, 1999, AM J EPIDEMIOL, V149, P884
[8]   Public health implications of legalising the production and sale of cannabis for medicinal and recreational use [J].
Hall, Wayne ;
Stjepanovic, Daniel ;
Caulkins, Jonathan ;
Lynskey, Michael ;
Leung, Janni ;
Campbell, Gabrielle ;
Degenhardt, Louisa .
LANCET, 2019, 394 (10208) :1580-1590
[9]   Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis [J].
Hindley, Guy ;
Beck, Katherine ;
Borgan, Faith ;
Ginestet, Cedric E. ;
McCutcheon, Robert ;
Kleinloog, Daniel ;
Ganesh, Suhas ;
Radhakrishnan, Rajiv ;
D'Souza, Deepak Cyril ;
Howes, Oliver D. .
LANCET PSYCHIATRY, 2020, 7 (04) :344-353
[10]   Excess of non-right-handedness in schizophrenia: meta-analysis of gender effects and potential biases in handedness assessment [J].
Hirnstein, Marco ;
Hugdahl, Kenneth .
BRITISH JOURNAL OF PSYCHIATRY, 2014, 205 (04) :260-+